The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia
Open accessAbstract
Specific combinations of acute myeloid leukemia (AML) disease alleles, including FLT3 and TET2 mutations, confer distinct biologic features and adverse outcome. We generated mice with mutations in Tet2 and Flt3, which resulted in fully penetrant, lethal AML. Multipotent Tet2(-/-);Flt3(ITD) progenitors (LSK CD48(+)CD150(-)) propagate disease in secondary recipients and were refractory to standard AML chemotherapy and FLT3-targeted therapy. Flt3(ITD) mutations and Tet2 loss cooperatively remodeled DNA methylation and gene expression to an extent not seen with either mutant allele alone, including at the Gata2 locus. Re-expression of Gata2 induced differentiation in AML stem cells and attenuated leukemogenesis. TET2 and FLT3 mutations cooperatively induce AML, with a defined leukemia stem cell population characterized by site-specific changes in DNA methylation and gene expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only combined loss of Tet2 and Dnmt3A (18) or presence of AML-associated gene lesions impairing myeloid cell maturation triggers malignant transformation of Tet2-deficient mouse HSC (13).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both of the latter develop a late-onset myeloproliferative phenotype (Supplementary Fig. S2B–S2I; refs. 13, 17).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is noteworthy that MPPGM (also commonly referred to as MPP3) (Challen et al., 2021) appears to be a nexus of myeloid expansion under both inflammatory conditions and in animal models of myeloid malignancy (Schepers et al., 2013; Pietras et al., 2015; Shih et al., 2015; Pietras et al., 2016; Herault et al., 2017; Hernandez et al., 2020; Kang et al., 2020; Rabe et al., 2020).”
From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Shih et al., 2015
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonnet, D. A., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 7,197 · cited 2×
“Transplantation studies of human leukemias demonstrated that leukemia initiating capacity is highest in CD34+CD38 stem cells (Bonnet and Dick, 1997).”
BackgroundMolecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111 · cited 2×
“Gene set enrichment analysis (GSEA) analysis showed that VTet2 / Flt3ITD LSK cells were characterized by enrichment of an embryonic stem cell signature and reduced expression of a GATA target signature (Figure 4C) (Liberzon et al., 2011; Wong et al., 2008).”
BackgroundConversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 1×
“TET2 catalyzes the 5-hydroxylation of methylcytosine to 5-hydroxymethylcytosine (5-hmC) leading to DNA demethylation (Guo et al., 2011; Tahiliani et al., 2009).”
BackgroundGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · cited 5×
“Although the combination of Tet2 and Flt3 mutations in our mouse model was sufficient to promote leukemogenesis, additional mutations and chromosomal alterations are sometimes seen in TET2;FLT3ITD mutant human AML (Cancer Genome Atlas Research Network, 2013), suggesting additional events may be required to transform h…”
BackgroundMethodInfluentialAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 2×
“Analysis of AML and normal subjects suggests mutations in TET2 and in epigenetic regulators can represent early acquiredmutations in ‘‘pre-leukemic’’ stem cells, which subsequently acquire further mutations leading to overt transformation (Genovese et al., 2014; Jaiswal et al., 2014; Jan et al., 2012).”
BackgroundClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531 · cited 1×
“…of AML and normal subjects suggests mutations in TET2 and in epigenetic regulators can represent early acquiredmutations in ‘‘pre-leukemic’’ stem cells, which subsequently acquire further mutations leading to overt transformation (Genovese et al., 2014; Jaiswal et al., 2014; Jan et al., 2012).”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 9×
“In addition, mutations in IDH1 and IDH2 inhibit TET2 function through production of 2-hydroxyglutarate (Figueroa et al., 2010), and WT1 mutations lead to reduced TET2 function and reductions in 5hmC (Rampal et al.”
BackgroundInfluentialSelf-citationmethylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles
Akalin, A., Kormáksson, M., Li, S., Garrett-Bakelman, F. E., Figueroa, M. E., Melnick, A. M., & Mason, C. E. (2012) · Genome biology · doi:10.1186/gb-2012-13-10-r87 · Cited by 2,269 · cited 8×
“Notably, of the 27 genes with promoter DMRs and differential expression, 19 were differentially methylated in TET2 mutant AML patients (Table S6) (Akalin et al., 2012a).”
BackgroundMethodInfluentialSelf-citationPrognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990 · cited 9×
“In particular, TET2mutations are associated with adverse outcome in the setting of concurrent FLT3ITD mutations (Hou et al., 2014; Patel et al., 2012), suggesting thesemutations cooperate to induce a poor-prognosis subtype.”
BackgroundInfluentialSelf-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–241 of 241
Clinical Applications of Epigenomics
McDevitt, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800140-0.00013-3 · Cited by 1
[Aberrant DNA methylation and its targeted therapy in acute myeloid leukemia].
Li, X., Zhu, L., & Ye, X. (2016) · PubMed Central · doi:10.3785/j.issn.1008-9292.2016.07.09 · Cited by 1
Inferring the Cancer Cellular Epigenome Heterogeneity via DNA Methylation Patterns
Li, S. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_12 · Cited by 1
Stem Cell Model of Hematologic Diseases
Taylor, J., & Abdel-Wahab, O. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00010-x · Cited by 1
Zheng, X., Li, X., Jiang, E., & Lv, L. (2021) · Research Square · doi:10.21203/rs.3.rs-1127079/v1 · Cited by 1
DNA methylation markers for early detection of colorectal cancer
Lentjes, M. H. F. M. (2016) · doi:10.26481/dis.20161202ml · Cited by 1
Halvarsson, C. (2018) · Linköping University medical dissertations · doi:10.3384/diss.diva-152129 · Cited by 1
Aziee, S., Yassim, H. M., Yusoff, S. M., Shamsuddin, S., Wahab, R. A., & Johan, M. F. (2019) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2019.027.3.02
Vitamin C Treatment Restores TET2 Deficiency and Confers Sensitivity to PARP Inhibition
Abdel-Wahab, O. I. (2017) · The Hematologist · doi:10.1182/hem.v14.6.7877
Bai, Y., Qin, Y., Fan, Z., Morrison, R. M., Nam, K. N., Zarour, H. M., Koldamova, R. P., Padiath, Q. S., Kim, S., & Park, H. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.30.229096
Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemiaPreprint
Stölzel, F., Fordham, S. E., Lin, W., Blair, H. J., Elstob, C. J., Nandana, D., Mohr, B., Ruhnke, L., Kunadt, D., Dill, C., et al. (2021) · medRxiv · doi:10.1101/2021.07.14.21259597
“Furthermore, Tet2 null (Tet2) mice with myeloid disease also have more pronounced splenomegaly compared to heterozygous (Tet2) littermates (33), and splenomegaly (and extramedullary disease) is a general feature of myeloid disease developing in Tet2 knockout mouse models (10, 34).”
BackgroundRomine, K. A., Cho, H.-J., Kosaka, Y., Byrd, K. H., Coy, J. L., Flynn, P. A., Newman, M., Loo, C. P., Scott, J., & Lind, E. F. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.04.455147
Ito, K., & Ito, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-56738-1.00002-6
Anti-cancer Activity of Vitamin-C Against Leukemia: A Review
Gupta, T., Vishwakarma, V. K., & Khan, M. K. M. |. K. (2018) · International Journal of Trend in Scientific Research and Development · doi:10.31142/ijtsrd14250
Schellhorn, H. E. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.729069935.793537498
Xie, J., Sheng, M., Rong, S., Wang, C., Wu, W., Huang, J., Sun, Y., Chen, P., Wu, Y., Wang, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.17.520899
Self-citationMeyer, S. E. (2023) · Blood · doi:10.1182/blood.2022019135
Aivalioti, M. M., Bartholdy, B., Pradhan, K., Bhagat, T. D., Zintiridou, A., Jeong, J. J., Thiruthuvanathan, V. J., Pujato, M. A., Paranjpe, A., Zhang, C., et al. (2023) · doi:10.1158/2643-3230.c.6550979
Self-citationAivalioti, M. M., Bartholdy, B., Pradhan, K., Bhagat, T. D., Zintiridou, A., Jeong, J. J., Thiruthuvanathan, V. J., Pujato, M. A., Paranjpe, A., Zhang, C., et al. (2023) · doi:10.1158/2643-3230.c.6550979.v1
Self-citationCell of origin epigenetic priming determines susceptibility to Tet2 mutationPreprint
Schiroli, G., Kartha, V. K., Duarte, F. M., Kristiansen, T. A., Mayerhofer, C., Shrestha, R., Earl, A., Hu, Y., Tay, T., Rhee, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.04.556230
Agustriawan, D., Darmawan, J. T., Permana, A. A., Overbeek, M. V., Yuliani, S., & Sitorus, B. B. (2024) · International Conference on Information Technology, Information Systems and Electrical Engineering (ICITISEE) · doi:10.1109/icitisee63424.2024.10730060
“The association between IDH2 and AML survival are various according to a previous study [10].”
BackgroundSwann, J. W., Fung, J. H., Chen, Z., Olson, O. C., Collins, A., Lhakhang, T. W., Proven, M. A., Zhang, R., Rabadán, R., & Passegue, E. A. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.05.007
Beckner, M. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.29.662144
Beckner, M. E. (2025) · Biomolecules · doi:10.3390/biom15081177
Ueda, K., Sato, Y., Minakawa, K., Miura, S., Hashimoto, Y., & Ikeda, K. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.105350
Additional file 1 of Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Brinton, L. T., Zhang, P., Williams, K., Canfield, D., Orwick, S. J., Sher, S., Wasmuth, R., Beaver, L., Cempre, C. B., Skinner, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13114679
Guan, W. P., Zhou, L., Li, Y., Yang, E., Liu, Y., Lv, N., Fu, L., Ding, Y., Wang, N., Fang, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14396478
Guan, W. P., Zhou, L., Li, Y., Yang, E., Liu, Y., Lv, N., Fu, L., Ding, Y., Wang, N., Fang, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14396481
Mims, A. S., Kohlschmidt, J., Borate, U., Blachly, J. S., Orwick, S. J., Eisfeld, A.-K., Papaioannou, D., Nicolet, D., Mrózek, K., Stein, E., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14833368
Self-citationAdditional file 2 of Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Brinton, L. T., Zhang, P., Williams, K., Canfield, D., Orwick, S. J., Sher, S., Wasmuth, R., Beaver, L., Cempre, C. B., Skinner, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13114682
Guan, W. P., Zhou, L., Li, Y., Yang, E., Liu, Y., Lv, N., Fu, L., Ding, Y., Wang, N., Fang, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14396472
Guan, W. P., Zhou, L., Li, Y., Yang, E., Liu, Y., Lv, N., Fu, L., Ding, Y., Wang, N., Fang, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14396469
Vela, P. S., Kelly, B., Brady, C., Foox, J., Glass, J. L., Koche, R. P., Wereski, M. G., Csete, I. S., Ghaity-Beckley, S. E., Marcellino, B. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700390
“Cooperating mutations in FLT3 promote progression to AML, NRAS to chronic myelomonocytic leukemia, and IDH2 to angioimmunoblastic T cell lymphoma (7-9).”
Self-citationQu, F., Hui, M., Yang, F., Wan, W., Liu, N., Wu, X., He, Y., & Wang, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1775927 · Cited by 1
“It is increasingly recognized that gene co-mutations often influence disease progression through complex synergistic mechanisms rather than simple additive effects (Shih et al., 2015; Mupo et al., 2013; Yao et al., 2024; Shahid et al., 2020).”
Bagacean, C. (2018) · theses.fr (ABES) · doi:10.70675/4409fbafz6d37z497cza3b9zf76d4e09d242
Rôle des cellules stromales périostéales dans la régénération de la niche hématopoïétique
Marchand, T. (2021) · theses.fr (ABES) · doi:10.70675/c12711fcz3a80z4ed4za5e8zec7f35f79a41
Lineage-specific lncRNAs critically determine cross-species differences in tumorsPreprint
Lin, J., Liu, X., & Zhu, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.01.722350
“…programs are evolutionarily conserved between humans and mice (Bradner et al., 2017; Krivtsov et al., 2006; Somervaille et al., 2009), and that leukemogenesis is driven primarily by cell-intrinsic epigenetic reprogramming and clonal evolution (Ferrando and Lopez-Otin, 2017; Shih et al., 2015).”
Goetz, M. L., Romer-Seibert, J. S., Versace, A. M., Kogan, S. C., Jeurkar, C., Bowman, R. L., Brooks, N., Frese, K., & Meyer, S. E. (2026) · Science Advances · doi:10.1126/sciadv.aec9305
“Collectively, these pathologic and immunophenotypic features, along with the presence of greater than 20 % immature forms/blast in the bone marrow and rapid lethality, are concordant with an AML diagnosis ( 42 ) and are consistent with other reports of similar mouse models ( 33 , 34 ).”
Ascorbate is a physiological tumor suppressor metabolite in leukemiaPreprint
Wijshake, T., Rose, J., Jun, J. H., Kwarteng, E. O., Yang, X., Zielke, J., Mahesula, S., Li, L., Chung, S. S., Comazzetto, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.20.760526 · Cited by 1
Metadata
- Authors
- Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., Robertson, A., Cavatore, M., de Stanchina, E., Hricik, T., Rapaport, F., Woods, B., Wei, C., Hatlen, M., Baljevic, M., Nimer, S. D., Tallman, M., Paietta, E., Cimmino, L., Aifantis, I., Steidl, U., Mason, C., Melnick, A., & Levine, R. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Weill Cornell Medicine (US)
- Albert Einstein College of Medicine (US)
- University of Miami (US)
- Montefiore Medical Center (US)
- Howard Hughes Medical Institute (US)
- Cornell University (US)
- Corresponding author
- Melnick, Ari
- Levine, Ross L.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 27
- Issue
- 4
- Pages
- 502-515
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4518555
- OpenAlex
- W1977440531
- Cited by
- 236
- References
- 50
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 12 · 2023: 15 · 2022: 18 · 2021: 22 · 2020: 25 · 2019: 23 · 2018: 19 · 2017: 33 · 2016: 31 · 2015: 11
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- National Human Genome Research Institute (R01HG006798)
- National Cancer Institute (U10CA180820, R01CA166429, CA172636-01, R01CA169784, R01CA173636, U10CA180827, U10CA021115, P30CA008748, P30CA013330, U24CA196172, R01CA166835)
- National Institute of Neurological Disorders and Stroke (R01NS076465)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- acute myeloid leukemia, TET2, FLT3-ITD, DNA methylation, GATA2, leukemia stem cells, leukemogenesis, mouse model, chemoresistance
- MeSH terms
- Antineoplastic Agents, Cell Differentiation, Cytarabine, DNA-Binding Proteins, Doxorubicin, Mutation, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute, Gene Expression Regulation, Neoplastic, DNA Methylation, Gene Silencing, Epigenesis, Genetic, Dioxygenases, GATA2 Transcription Factor, fms-Like Tyrosine Kinase 3, Haploinsufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
